Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: Open, observational study in 31793 patients

Current Medical Research and Opinion

Volumn 21, Issue 9, 2005, Pages 1433-1440

  Strutz, Frank ^a,d   Bramlage, P ^b,c   Paar, W D ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Cardiovascular risk; Hypertension; Irbesartan; Microalbuminuria; Pulse pressure; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PULSE PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG TOLERANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBSERVATION; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 25444503538     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X61811     Document Type: Article

References (36)

1. Arauz-Pacheco C, et al. Treatment of hypertension in adults with diabetes. American Diabetes Association position statement. Diabetes Care 2003;26(Suppl 1):S80-2
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19(5):403-18
3. Bloomgarden ZT. Diabetes and hypertension. Diabetes Care 2001;24:1679-84
4. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011-53
5. Sharma AM, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22(3):479-86
6. Pittrow D, Wittchen H, Kirch W. Hypertension and diabetes care among primary care doctors in Germany: results from an epidemiological cross-sectional study. In: Kirch W, editor. Public health in Europe. Berlin: Springer-Verlag; 2004. p. 203-18
7. Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998;351(9118):1755-62
8. Hansson L, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354(9192):1751-6
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317(7160):703-13
10. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138(7):593-602
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53
12. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127(9):788-95
13. Fogari R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring [Irbesartan Multicenter Investigators' Group]. J Hypertens 1997;15(12 Pt 1):1511-8
14. Raskin P, et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999;13(10):683-7
15. Larochelle P, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension [Irbesartan Multicenter Investigators]. Am J Cardiol 1997;80(12):1613-5
16. Stumpe KO, et al. Comparison of the angiotensin-II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998;7(1):31-7
17. Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med 2001;345(12):870-8
18. Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001;345(12):851-60
19. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289(19):2560-72
20. Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 2003;20(12):972-87
21. SAS and C. SAS Institute Inc., NC, 1999
22. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care. Curr Med Res Opin 2004;20(10):1625-31
23. Lehnert H, et al. Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment. An observational study in 38 016 patients in primary care. Clin Drug Invest 2004;24:217-25
24. Adler AI, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000;321(7258):412-9
25. Bakris GL, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163(13):1555-65
26. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin-II antagonist. J Hypertens Suppl 2001;19(Suppl 1):S41-8
27. Conlin PR, et al. Angiotensin-II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13(4 Pt 1):418-26
28. Franklin SS, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96(1):308-15
29. Gasowski J, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens 2002;20(1):145-51
30. Blacher J, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160(8):1085-9
31. Scholze J. Pulse pressure in the therapeutic management of hypertension? [In German]. Herz 2004;29(3):276-89
32. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000;160(16):2447-52
33. Croom KF, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64(9):999-1028
34. Schulte K, Fischer M, Meyer-Sabellek W. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs: results of the AURA study. Clin Drug Invest 1999;18:453-60
35. Scholze J, et al. Valsartan alone and in combination with hydrochlorothiazide in general practice: results from two postmarketing surveillance studies involving 54 928 patients with essential hypertension. Clin Drug Invest 2000;20:1-7
36. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;342(25):1887-92